Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
CI,
Not wanting to throw too much water on the fire, but the statement "we are now more hopeful that the royalty income
will experience exponential growth from 2023 and beyond" is misleading given it is referring to sales in "Europe" which you have appeared to miss in your cut'n'paste. The statement is of course made by JM who always makes absurd statements in the reports and the public domain (remember the "money tree" from 8 years ago) as well as other such guffs.
Even with OTC, which will have a huge discount/can, I cannot see huge sales coming in given the initial launch was a disaster with sales, in their word, "disappointing". They would need to sell probably more than double the number of cans to even come close to the expected income/royalty as projected when first launched.
What I am positive about, however, are the launches in China, which could happen next year, and not so much the US which, based on the way the company has "endeavored to bring the product to market as soon as possible" statements before, will, I am sure, take much longer (phase II = 4+ years). That's unless a licensee steps in and takes control which should accelerate matters since "money talks".
I may be wrong, but I feel China will be the turning point given the number of sufferers we are looking at (nearly 5 times that of the US). Even with a discounted price / can, it should still add up to a reasonable amount which should increase exponentially.... ;-)
just my opinion of course ;-)
So I would suspect its due to the capital reduction, otherwise everything else is quite positive.
The markets always knee jerk over react. Just have to look at the drops around the world these last few weeks due to the banking scares. And these knee jerks have become more volatile due to the impacts of inflation and interest rates following 3 years of covid, however. When they turn, they can jump pretty quickly which, I’m sure, will happen here.
The writings in the report do indicate a lot more than usual that things will start to come good this year.
Just my opinion of course ;-)
The.Italian,
Totally agree, however. Surely due to the recent rights issue, there are effectively less free shares to trade, even if the dilution increased the number by 2 it must have an impact on what's freely available. Would this become even more apparent with the 20 to 1 consolidation and the number of free shares although I still don't understand the need for 20 to 1 as opposed to 5 to 1 ?
That’s the MnMs for you, given the report effectively stated the company was worthless, but still ended with more buys than sells. I’m sure this will pickup again once the announcement of the Chinese NDA submission and FDA approval to commence phase iii are made, although still a few months to go before the Chinese submission yet. Mind you they have always been ahead of the curve so we may receive a notification sooner.
Any more profit warnings and the company on paper will be less than worthless….lol
And of course they did state it would increase liquidity....lol
Well….That certainly had a positive impact to the sp :-O
Morning The.Italian.
Well it certainly adds a little to the op update with more positivity on both the US and China fronts, however. I notice there will be a 20 to 1 consolidation (page 28) meaning there will only be near 230 mill shares in circulation. which would in effect increase the SP to around 1.5 which is certainly more than your 0,4 prediction....lol.
That said; with such a reduction in the number of shares will give them the opportunity to issue a shti load more to undeserving institutions with the effect of huge dilution to ourselves. This seems to be more likely than not, otherwise why not consolidate by 5 giving a more acceptable billion shares.
They also state they have 7 mill usd in the bank which as stated earlier in the document would see them through for the next 12 months, however. Does this also include the costs of phase III ?
Not much info on the manufacturer supplying Asia and recommencement of sales ?
Also, they state they have managed to sign their first customers (which means B2B, so corporations) regarding the DLI app yet no mention of what the terms are or how it will contribute to the 7 mill usd for the next 12 months ? It certainly would appear to be not a very lucrative deal otherwise they would surely be shouting from the rooftops ???
Yup, The usual smoke an mirrors on many fronts.
Well I would hazard a guess that Longevity is no longer flavour of the month. The white elephant in the cupboard will be put out to graze and they will move on to some new venture. As to what that is, is anyones guess.
Yup, since they were already a laughing stock, now they are just proving to everyone they were and are indeed incompetent.
Comedy hour………
But I’m sure it’s for some other reason than what they have stated since RPG had a carp reputation to begin with. How embarrassing Jim, how embarrassing.
Regarding terms of reference of the renumeration committee. Strange this would be uploaded first. And ominous since they obviously want to change renumeration for the quality work done in the last few years… :-O
The way FUM have proceeded in getting this far certainly makes ERPs efforts comical. And we were supposed to have had an unambiguous FDA way forward back in March 2014 !!!
If the market responds well to just a confirmatory RNS about a response, imagine what the market response to approval news could be….. lol
Results which could contain a small update re FDA and China due any minute now.
Morning The.Italian.
I see a small FUM RNS has been uploaded to say a response to FDA has been made and they are on track to receive approval in Q2. Luckily, I bought a few more a few days ago.
That’s 6 to 7 weeks before and after the rise so 12 to 14 weeks….lol
Is there really such a thing as a long pump ‘n’ dump ?
A rise to over 4A$ and back to 2.75A$ in a 6 to 7 week turnaround ?
And luckily for me, the buy was processed after the 7%+ drop..... ;-)
Only time will tell on that, however. It’s more likely they receive FDA approval than not.